<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1030">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04576312</url>
  </required_header>
  <id_info>
    <org_study_id>UNI911-101</org_study_id>
    <nct_id>NCT04576312</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19</brief_title>
  <official_title>Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNION therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNION therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to
      Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in
      Preparation for Evaluation in Adults with COVID-19
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to
      Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in
      Preparation for Evaluation in Adults with COVID-19

      44 subjects will be sequentially enrolled to receive dosage of UNI911 INHALATION or placebo.
      4 sentinel subjects (one per cohort 1, 2 ,3 and 4 ) will be treated in an open-label manner
      to confirm the safety of each dose sequentially. The remaining 40 subjects will be randomly
      assigned (3:1) to either active or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess safety of UNI911 INHALATION in healthy volunteers: AE frequency</measure>
    <time_frame>Up to Day 6</time_frame>
    <description>AE frequency in each cohort and treatment group</description>
  </primary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Parameters: Cmax</measure>
    <time_frame>Up to Day 4 of participant treatment</time_frame>
    <description>Maximum concentration of active drug molecules in blood (Cmax)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Parameters: Tmax</measure>
    <time_frame>Up to Day 4 of participant treatment</time_frame>
    <description>Time to reach maximum level (Tmax)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Parameters: AUC</measure>
    <time_frame>Up to Day 4 of participant treatment</time_frame>
    <description>Area Under the Curve of drug level in blood versus time (AUC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Parameters: Half life</measure>
    <time_frame>Up to Day 4 of participant treatment</time_frame>
    <description>Half life</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP Single and Total Dose* (Inhalation): 4 mL0.1% / 3.4 mg Duration of Treatment: 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP Single and Total Dose* (Inhalation): 1 mL1% /8.4 mg Duration of Treatment: 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP Single and Total Dose* (Inhalation): 3 mL1%/25.2 mg Duration of Treatment: 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP Single and Total Dose* (Inhalation): 6 mL 1% /50.5 mg Duration of Treatment: 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP Single and Total Dose* (Inhalation): 6 mL1% /50.5mg 30 mL/252mg Duration of Treatment: 2.5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UNI911 INHALATION</intervention_name>
    <description>UNI911 INHALATION</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (main ones):

          1. Signed Informed Consent Form (ICF)

          2. Male or non-pregnant and non-lactating female who is abstinent or agrees to use
             effective contraceptive methods throughout the course of the study. Females must have
             a negative urine beta-human chorionic gonadotropin hormone (hCG) pregnancy test prior
             to dosing. (Women who are postmenopausal or who had tubal ligation/hysterectomy do not
             need to have a pregnancy test done and do not need to agree to use contraception.)

          3. ECG without clinically significant abnormalities (including QTcF &lt; 450 ms)

          4. Age ≥ 18 and &lt; 65 years at the time of signing ICF

          5. Normally active and in good health by medical history and physical examination

          6. Minimum 80% of predicted lung function, including FEV1 after beta2-agonist, TLC, DCO,
             and CPET with pulse oximetry

          7. Chest X-ray without clinically significant abnormalities

        Exclusion Criteria (main ones):

          1. Enrollment in an UNI911 study in the previous 6 months

          2. Clinically significant allergy (as judged by the investigator) or history of
             significant adverse reaction to niclosamide or related compounds, to any of the
             excipients used.

          3. Underlying condition that may interfere with inhalation of the IP

          4. Current acute or chronic condition (incl. COPD, asthma, or other severe respiratory
             disease, CV disease, diabetes mellitus, obesity, malignant and autoimmune diseases)
             unless considered clinically irrelevant and stable by the investigator

          5. Renal impairment (eGFR &lt; 60 mL/min/1.73m2) or hepatic impairment (as judged by the
             investigator)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulf Sjöbring, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UNION therapeutics A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mads Jellingsø</last_name>
    <phone>+(45)53523044</phone>
    <email>info@uniontherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wanja Nyoro</last_name>
    <phone>+(45)61632069</phone>
    <email>info@uniontherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DanTrials</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torben Balchen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

